Literature DB >> 25965438

Postoperative resource utilization and survival among liver transplant recipients with Model for End-stage Liver Disease score ≥ 40: A retrospective cohort study.

Filipe S Cardoso, Constantine J Karvellas, Norman M Kneteman, Glenda Meeberg, Pedro Fidalgo, Sean M Bagshaw.   

Abstract

BACKGROUND: Cirrhotic patients with Model for End-stage Liver Disease (MELD) score ≥ 40 have high risk for death without liver transplant (LT).
OBJECTIVE: To evaluate these patients' outcomes after LT.
METHODS: The present study analyzed a retrospective cohort of 519 cirrhotic adult patients who underwent LT at a single Canadian centre between 2002 and 2012. Primary exposure was severity of liver disease measured by MELD score at LT (≥ 40 versus < 40). Primary outcome was duration of first intensive care unit (ICU) stay after LT. Secondary outcomes were duration of first hospital stay after LT, rate of ICU readmission, re-LT and survival rates.
RESULTS: On the day of LT, 5% (28 of 519) of patients had a MELD score ≥ 40. These patients had longer first ICU stays after LT (14 versus two days; P < 0.001). MELD score ≥ 40 at LT was independently associated with first ICU stay after LT ≥ 10 days (OR 3.21). These patients had longer first hospital stays after LT (45 versus 18 days; P < 0.001); however, there was no significant difference in the rate of ICU readmission (18% versus 22%; P = 0.58) or re-LT rate (4% versus 4%; P = 1.00). Cumulative survival at one month, three months, one year, three years and five years was 98%, 96%, 90%, 79% and 72%, respectively. There was no significant difference in cumulative survival stratified according to MELD score ≥ 40 versus < 40 at LT (P = 0.59).
CONCLUSIONS: Cirrhotic patients with MELD score ≥ 40 at LT utilize greater postoperative health resources; however, they derive similar long-term survival benefit from LT.

Entities:  

Mesh:

Year:  2015        PMID: 25965438      PMCID: PMC4444027          DOI: 10.1155/2015/954656

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  30 in total

1.  Dealing with missing outcome data in randomized trials and observational studies.

Authors:  Rolf H H Groenwold; A Rogier T Donders; Kit C B Roes; Frank E Harrell; Karel G M Moons
Journal:  Am J Epidemiol       Date:  2011-12-23       Impact factor: 4.897

Review 2.  Hepatopulmonary syndrome.

Authors:  Victor I Machicao; Michael B Fallon
Journal:  Semin Respir Crit Care Med       Date:  2012-03-23       Impact factor: 3.119

3.  The MELD score in patients awaiting liver transplant: strengths and weaknesses.

Authors:  Mauro Bernardi; Stefano Gitto; Maurizio Biselli
Journal:  J Hepatol       Date:  2010-11-20       Impact factor: 25.083

4.  End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates.

Authors:  Pratima Sharma; Douglas E Schaubel; Qi Gong; Mary Guidinger; Robert M Merion
Journal:  Hepatology       Date:  2011-11-15       Impact factor: 17.425

5.  Outcomes after liver transplantation in patients achieving a model for end-stage liver disease score of 40 or higher.

Authors:  Sophoclis Alexopoulos; Lea Matsuoka; Yong Cho; Elizabeth Thomas; Mohd Sheikh; Maria Stapfer; Kiran Dhanireddy; Linda Sher; Rick Selby; Yuri Genyk
Journal:  Transplantation       Date:  2013-02-15       Impact factor: 4.939

6.  Improved survival after liver transplantation in patients with hepatopulmonary syndrome.

Authors:  S Gupta; H Castel; R V Rao; M Picard; L Lilly; M E Faughnan; G Pomier-Layrargues
Journal:  Am J Transplant       Date:  2009-09-22       Impact factor: 8.086

7.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

Authors:  Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo
Journal:  Gastroenterology       Date:  2013-03-06       Impact factor: 22.682

8.  Outcome after liver transplantation for cirrhosis due to alcohol and hepatitis C: comparison to alcoholic cirrhosis and hepatitis C cirrhosis.

Authors:  Ashwani K Singal; Bashar S Hmoud; Praveen Guturu; Yong-Fang Kuo
Journal:  J Clin Gastroenterol       Date:  2013-09       Impact factor: 3.062

9.  Outcomes with split liver transplantation are equivalent to those with whole organ transplantation.

Authors:  M B Majella Doyle; Erin Maynard; Yiing Lin; Neeta Vachharajani; Surendra Shenoy; Christopher Anderson; Mark Earl; Jeffrey A Lowell; William C Chapman
Journal:  J Am Coll Surg       Date:  2013-04-30       Impact factor: 6.113

10.  The impact of organ dysfunction in cirrhosis: survival at a cost?

Authors:  Debbie L Shawcross; Mark J Austin; Robin Daniel Abeles; Mark J W McPhail; Andrew D Yeoman; Nicholas J Taylor; Andrew J Portal; Khaleel Jamil; Georg Auzinger; Elizabeth Sizer; William Bernal; Julia A Wendon
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

View more
  4 in total

1.  Single-Center Experience on Liver Transplantation for Model for End-Stage Liver Disease Score 40 Patients.

Authors:  Georgios C Sotiropoulos; Spyridon Vernadakis; Andreas Paul; Dieter P Hoyer; Fuat H Saner; Anja Gallinat
Journal:  Dig Dis Sci       Date:  2016-08-18       Impact factor: 3.199

2.  The Perme scale score as a predictor of functional status and complications after discharge from the intensive care unit in patients undergoing liver transplantation.

Authors:  Camila Santos Pereira; Alexandra Torres de Carvalho; Adriane Dal Bosco; Luiz Alberto Forgiarini Júnior
Journal:  Rev Bras Ter Intensiva       Date:  2019 Jan-Mar

3.  Pretransplant Factors and Associations with Postoperative Respiratory Failure, ICU Length of Stay, and Short-Term Survival after Liver Transplantation in a High MELD Population.

Authors:  Mark R Pedersen; Myunghan Choi; Jeffrey A Brink; Anil B Seetharam
Journal:  J Transplant       Date:  2016-11-17

Review 4.  Approaches for patients with very high MELD scores.

Authors:  Florent Artru; Didier Samuel
Journal:  JHEP Rep       Date:  2019-02-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.